CAJ | 학술논문

目的：研究吉非替尼对肺鳞癌患者免疫功能的影响及其近期临床疗效。方法选取诊断为肺鳞癌的患者84例，随机分为观察组和对照组，每组均为42例，两组患者均给予常规治疗，观察组在常规治疗的基础上给予口服吉非替尼，观察两组患者治疗后体液免疫和细胞免疫功能情况及其近期临床疗效。结果治疗后两组患者血清 CD3、CD4、IgG、IgM、IgA 浓度与 CD4／CD8较治疗前有所降低（P ＜0．05），CD8较治疗前有所升高（P ＜0．05）；观察组患者血清 CD3、CD4、CD4／CD8、IgG、IgM、IgA 浓度明显高于对照组（P ＜0．05），观察组 CD8较对照组低（P ＜0．05）；观察组临床疗效优于对照组，治疗后两组均出现恶心、恶心伴呕吐、骨髓抑制，差异无统计学意义（P ＞0．05）。结论在常规治疗的基础上给予口服吉非替尼能改善患者的免疫功能，提高临床疗效，且无严重不良反应。
목적：연구길비체니대폐린암환자면역공능적영향급기근기림상료효。방법선취진단위폐린암적환자84례，수궤분위관찰조화대조조，매조균위42례，량조환자균급여상규치료，관찰조재상규치료적기출상급여구복길비체니，관찰량조환자치료후체액면역화세포면역공능정황급기근기림상료효。결과치료후량조환자혈청 CD3、CD4、IgG、IgM、IgA 농도여 CD4／CD8교치료전유소강저（P ＜0．05），CD8교치료전유소승고（P ＜0．05）；관찰조환자혈청 CD3、CD4、CD4／CD8、IgG、IgM、IgA 농도명현고우대조조（P ＜0．05），관찰조 CD8교대조조저（P ＜0．05）；관찰조림상료효우우대조조，치료후량조균출현악심、악심반구토、골수억제，차이무통계학의의（P ＞0．05）。결론재상규치료적기출상급여구복길비체니능개선환자적면역공능，제고림상료효，차무엄중불량반응。
Objective To study the effect of gefitinib on immune function and clinical efficacy in patients with lung squamous cell canc-er.Methods Eighty-four patients who suffered from lung squamous cell cancer were randomized into observation group and control group.They were treated with conventional treatment,and the observation group took oral Gefitinib on this basis.The concentration of tumour markers in serum and efficacy were observed and compared between the two groups after treatment.Results After treatment, the concentration of CD3,CD4,IgG,IgM,IgA and CD4 /CD 8were lower than pretreatment levels(P <0.05),the concentration of CD 8 was higher than pretreatment levels(P <0.05),and the concentration of CD3,CD4,IgG,IgM,IgA and CD4 /CD8 in the observation group were significantly higher than those in the control group(P <0.05),the concentration of CD8 in the observation group was signif-icantly lower than that in the control group(P <0.05).After treatment,the clinical efficiency in the observation group was significantly higher than control group.After treatment,nausea,nausea plus vomit,and myelosuppression occurred in both groups,which had no sta-tistical difference(P >0.05).Conclusions Gefitinib can improve the immune function and raise the clinical efficiency of patients with lung squamous cell cancer.